Abstract
4 of striatal glutamatergic transmission, which impedes the characteristic degeneration of striatal neurons. 25 Importantly, it has recently been shown in induced pluripotent stem cellsderived neurons that glutamate overstimulation raises intracellular calcium levels activating the cysteine proteases calpains and promoting the proteolysis and aggregation of ataxin-3.
26
Moreover, calpain-mediated proteolysis of ataxin-3 in a rodent model of MJD mediates translocation of ataxin-3 to the cell nucleus, aggregation and neurodegeneration, which can be prevented by calpain inhibition. 27 In view of this proposed key role of glutamate overstimulation in MJD, we now investigated the time course of neuropathological modifications in a genetic model of MJD and tested the novel hypothesis that the manipulation of A 2A R function might also be beneficial in MJD.
Materials and Methods

Animals
Male C57BL/6 mice (Charles River, Barcelona, Spain) were housed and kept under a conventional 12-h light-dark cycle maintained on a temperature-controlled room with food and water provided ad libitum and used at 7 weeks of age. C57Bl/6-background A 2A R knockout (A 2A R KO) and age-matched wild type control mice were obtained from parallel breeding of our colony of A 2A R KO mice, initially obtained from J.F.Chen (Boston University). 28 The experiments were carried out in accordance with the European Community directive (86/609/EEC) for the care and use of laboratory animals.
Drug treatment
We chose the dose of caffeine (1 g/L) administered through the drinking water, as a maximally effective and non-toxic dose, which we have previously shown to result in a plasma concentration of 50 µM, 29 and similar concentration in the brain parenchyma, 30 corresponding to a diary human consumption of circa 5 cups of coffee. Treatment with caffeine was begun 3 weeks before viral delivery onwards, since we have previously
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reported that a minimum period of 2 weeks is required to allow a metabolic stabilization after beginning the free access to caffeine drinking.
29, 31
Viral vectors production
Lentiviral vectors encoding human wild-type ataxin-3 (atx3-27Q) or mutant ataxin-3 (atx3-72Q), 8 were produced in 293T cells with a four-plasmid system, as previously described. 32 The lentiviral particles were resuspended in 1% bovine serum albumin in phosphate-buffered saline (PBS). The viral particle content of batches was determined by assessing HIV-1 p24 antigen levels (RETROtek, Gentaur, Paris, France). Viral stocks were stored at -80ºC until use.
In vivo injection into the striatum
Concentrated viral stocks were thawed on ice. After anesthesia of the mice with avertin (12 µL/g, i.p.), lentiviral vectors encoding human wild-type (atx3-27Q) or mutant ataxin-3 (atx3-72Q) were stereotaxically injected into the striatum in the following coordinates: anteroposterior: +0,6mm; lateral: ±1,8mm; ventral: -3,3mm; tooth bar: 0, which corresponds to the internal capsule, a large fiber tract passing through the middle of the striatum dividing both dorso-ventral and medial-lateral structures. Wild-type and A 2A R KO mice received 2 µL injections of lentivirus (200'000 ng of p24/mL) in each hemisphere, administering mutated ataxin-3 (atx3-72Q) in the right hemisphere and control wild type ataxin-3 (atx3-27Q) in the left hemisphere. Different groups of mice were kept in their home cages for different periods ranging from 2, 4, 8 and 12 weeks, before being killed for immunohistochemical analysis of morphological and neurochemical changes in the striatum.
Immunohistochemical procedure
After an overdose of avertin (2.5x 12 µL/g, i.p.), transcardiac perfusion of the mice was performed with PBS followed by fixation with 4% paraformaldehyde. The brains were then removed and post-fixed in 4% paraformaldehyde for 24h and cryoprotected by incubation in 25% sucrose/ phosphate buffer for 48h. The brains were frozen and 25 µm coronal sections 6 were cut using a cryostat (LEICA CM3050 S, Heidelberg, Germany) at -21°C. Slices throughout the entire striatum were collected in anatomical series and stored in 48-well trays as free-floating sections in PBS supplemented with 0.05 µM sodium azide. The trays were stored at 4°C until immunohistochemical processing.
Sections were processed overnight at 4ºC with the following primary antibodies: a mouse monoclonal anti-ataxin-3 antibody (1H9; 1:5000; Chemicon, Temecula, CA), a rabbit anti-DARPP-32 antibody (1:1000; Chemicon), or a mouse anti-NeuN antibody (1:1000;
Chemicon) followed by 2h incubation at room temperature (RT) with the respective biotinylated secondary antibodies (1:200; Vector Laboratories, Burlingame, CA). Bound antibodies were visualized using the Vectastain ABC kit, with 3,3'-diaminobenzidine tetrahydrochloride (DAB metal concentrate; Pierce, Burlingame, CA) as substrate.
Triple staining for synaptophysin (rabbit polyclonal, 1:300; Chemicon) and MAP2
(mouse monoclonal AP20, 1:500; Santa Cruz Biotechnology, Santa Cruz, CA), GFAP (rabbit polyclonal, 1:1000; DAKO, Glostrup, Denmark) and CD11b (rat monoclonal 5C6, 1:500; AbD Definition and analysis of protein immunoreactivities were made from the striatal center (site of injection) to the medial-lateral and dorsal-ventral striatal periphery from the needle tract. This disease model is based on the intra-striatal injection of lentivirus, which triggers physiological alterations evolving over time radially. Therefore, comparable striatal sections 7 between animals were defined from the site of injection in both rostral and caudal directions, using the needle tract due to the surgical procedure as reference-point. 
Cresyl violet staining
Coronal sections were pre-mounted and stained with cresyl violet for 45 sec, differentiated in 70% ethanol, dehydrated by passing twice through 95% ethanol, 100%
ethanol and xylene solutions, and mounted onto microscope slides with Eukitt ® (Sigma).
Evaluation of the volume of the DARPP-32 depleted volume and optic density
The extent of ataxin-3 lesions in the striatum was analyzed by photographing, with a immunoreactivity.
Cell counts of ataxin-3 inclusions
Coronal sections showing complete rostro-caudal sampling (1 of 8 sections) of the striatum were scanned with a x20 objective. The analyzed areas of the striatum 8 encompassed the entire region containing ataxin-3 inclusions, as revealed by staining with the anti-ataxin-3 antibody. All inclusions were manually counted using a semi-automated image-analysis software package (Image J software).
Statistical analysis
Statistical comparisons were performed using either an unpaired Student's t test or one-way analysis of variance (ANOVA) followed by Dunnett's multiple comparison post hoc test. Results are expressed as mean ± standard error of the mean (SEM). Significance thresholds were set at p < 0.05, p < 0.01 or p < 0.001, as defined in the text.
Results
Time course
We took advantage of using a lentiviral model of MJD to perform a temporal analysis of the relative appearance of different features from early dysfunction to late neuronal loss.
Thus, we carried out a time-course study from 2 to 12 weeks upon lentiviral-mediated expression of wild-type and mutant ataxin-3, and we analysed different neuropathological features such as markers of synaptic loss, neuronal dysfunction, neuronal loss, of astrogliosis and microgliosis as well as ataxin-3 inclusions. Figure 1 summarises the temporal evolution of each of these changes, which will be further detailed below. To further investigate the neuroprotective effects of caffeine at a late time-point in this model of MJD, we evaluated the immunoreactivity of the neuronal nuclear marker NeuN. A clear loss of NeuN-stained neurons could be seen in the water-drinking group at 12 weeks after mutant ataxin-3 transduction, which was not detectable after wild-type ataxin-3 transduction, and was nearly absent in mutant ataxin-3-expressing animals upon caffeine treatment ( Fig 2C) .
Neuronal degeneration and loss
In order to directly test if caffeine and
These data suggest that there is a progression in the degeneration pattern in MJDassociated striatal pathology leading to loss of neuronal markers, which is reduced by chronic caffeine consumption as well as genetically deleting the A 2A R.
Neuronal functional modifications
Previous reports have indicated that striatal neuronal dysfunction may precede degeneration and appearance of clinical symptoms in MJD. 33 Additionally, DARPP-32
(dopamine and cAMP-regulated phosphoprotein) was previously shown to be a sensitive marker that allows immunohistochemical detection of this early neuronal dysfunction. (Table 1) showed a significant preservation of this marker in caffeine-treated (p < 0.01) and A 2A R KO groups (p < 0.05) at 12 weeks post-injection of lentivirus encoding atx3-72Q, as compared to the respective water-drinking groups.
These data suggest that both chronic caffeine consumption as well as the genetic deletion of A 2A R is able to reduce neuronal dysfunction in MJD.
Astrogliosis and microgliosis
Interestingly, the mutant ataxin-3-induced loss of NeuN immunoreactivity was accompanied by a local increase of GFAP immunoreactivity suggestive of astrocytic activation, which was nearly absent in caffeine-treated animals ( Fig 2D) . Since reactive gliosis is widely accepted to contribute to chronic neurodegenerative diseases, we further investigated if the blockade of A 2A R was able to prevent the increase of gliosis associated with MJD pathogenesis at an early time-point. The injection of lentiviral vectors encoding mutant ataxin-3 (LV-atx3-72Q) triggered a robust increase of GFAP immunoreactivity at 4
weeks when compared with the contralateral striatum challenged with wild-type ataxin-3 (LVatx3-27Q) (Fig 4A) . Notably, this GFAP immunoreactivity triggered by expression of mutated ataxin-3 was observed as early as 2 weeks (Fig 4B) . Additionally, strong immunoreactivity for the microglial protein, cluster of differentiation molecule B11 (CD11b), was found at 4 weeks revealing microglial recruitment (Fig 4C) , which was significantly and robustly reduced in caffeine-treated animals. This clearly establishes the presence of reactive gliosis in the striatum in this genetic model of MJD.
Importantly, treatment with caffeine (1 g/L), prevented both the astrogliosis (Fig 4A and   B ) and the putative microgliosis (Fig 4C) triggered by mutant ataxin-3 indicating that chronic caffeine consumption can prevent reactive gliosis associated with MJD.
Nuclear inclusions of mutant ataxin-3
Since microglia is well established to play a role in the seeding (through enhanced inflammatory status) and processing (through phagocytosis) of protein aggregates and the presence of ataxin-3 aggregates is one hallmark of MJD, we next tested the impact of caffeine and A 2A R inactivation on the aggregation pattern of ataxin-3 by immunohistochemical staining. No aggregation was seen upon LV-atx3-27Q injection ( Fig   5A) while a significant increase in the total number of mutant ataxin-3 nuclear inclusions was observed at 8 weeks post-injection of lentiviral vectors encoding mutant ataxin-3 in both caffeine-drinking wild type mice (p < 0.05) as well as in A 2A R KO animals (p < 0.05) when compared to the respective water-drinking groups (Fig 5B and C) . Interestingly, we previously demonstrated that at 8 weeks after lentiviral transduction there were 4 times higher striatal levels of mutant ataxin-3 than those of endogenous ataxin-3, 8 although the levels were similar 4 weeks after lentiviral administration. This observation that caffeine or A 2A R inactivation enhance even more the number of ataxin-3 inclusions while decreasing neurodegeneration is in agreement with the scenario that these inclusions may be a way to sequester the soluble and noxious forms of ataxin-3.
Synaptotoxicity
There is accumulating evidence that one of the earliest features of neurodegenerative diseases is the dysfunction and loss of synapses. 
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Density analysis of synaptophysin and MAP-2 immunoreactivities at 2 weeks postinjection (Table 2 and Fig 6) clearly showed a significant loss of both markers (p < 0.001) upon mutant ataxin-3 expression. No such early loss of either markers was observed in caffeine-drinking mice challenged with atx3-72Q, i.e. 2 weeks after insult or upon expression of wild-type ataxin-3 (data not shown). These data provide the first evidence that mutant ataxin-3 induces an early synaptotoxicity in the striatum, which is prevented by chronic caffeine consumption.
Discussion
In the present study, we carried out a temporal analysis of different features of brain Synaptotoxicity is in line with suggestions of axonal degeneration assessed by MRI, 38 and loss of dopaminergic terminals assessed by PET in MJD patients, 11 and with the presence of axonal inclusions in the human patient's brains, 39 as well as with the observed impact of mutant ataxin-3 on the cerebellar mRNA expression of proteins involved in synaptic transmission. 40 Notably, the present time course study provides direct evidence that this synaptotoxicity might be an early, hitherto unrecognised, feature of MJD. This is in notable agreement with the observations that another polyglutamine-related disease, namely
Huntington's disease is characterized by early changes in synapses, 41, 42 to such an extent
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that it has been proposed that Huntington's disease might actually be a synaptopathy. 43 Actually, it is worth noting that synaptotoxicity seems to be an early feature of different other neurodegenerative and neuropsychiatric diseases, strengthening the crucial role of synaptic impairment in the initiation of brain disorders. 22, 36, 44 Since there is evidence that ataxin-3 is also located in axons and dendrites, 45 the present observation that synaptic changes are an early feature of MJD opens a new area of research on the putative role of ataxin-3 in the control of synaptic function and damage. In this context, the recent report that excitatory synaptic transmission can control the aggregation of mutant ataxin-3 adds a further dimension to the relation between MJD and synaptic activity.
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The present time course study of striatal changes in this MJD model also revealed another under-appreciated morphological feature that predated neuronal dysfunction and damage, namely reactive gliosis. There has been episodic reports of astrogliosis and microgliosis, typified by changes in astrocytes and microglia morphology both in patients, 46 and in transgenic models of MJD, 47 as well as increased expression of cytokines and proinflammatory chemokines, which are compatible with mutant ataxin 3-induced changes in brain inflammatory mediators. 48 However, in keeping with the fact that our lentiviral-mouse model resulted in an overexpression of mutant ataxin-3 even in comparable levels to the endogenous form, the present report provides evidence that reactive astrogliosis might be an proposal that synaptotoxicity might be a precocious modification in MJD, several studies highlight the importance of the ubiquitin-proteosome system (UPS) in synapses, 70, 71 namely in presynaptic terminals, 72, 73 where it is affected in other polyQ neurological diseases; 74 furthermore, there is preliminary evidence that A 2A Rs directly bind to UPS components, 75 and control the UPS activity, 76 paving the way for a putative direct control by A 2A R of synaptic UPS. The proposal that the ability of A 2A Rs to control another polyQ neurological disorder (Huntington's disease) depends on the control of glutamatergic transmission prompts an alternative mechanism by which the A 2A R-mediated control of the initial event in MJD might be related to the ability of A 2A R to control abnormal glutamatergic transmission through direct synaptic effects, 77 or indirectly through control of astrocytic glutamate uptake. 78, 79 Thus, albeit the molecular mechanism of A 2A R-mediated control of MJD remains to be determined, the present study provides new clues for particular compartments where such mechanisms should be explored.
In conclusion, the present study provides a novel insight into the pathology of MJD bringing to the centre stage synaptotoxicity and gliosis as precocious events in MJD.
Furthermore, it provides the first realistic and safe promising life style prophylactic strategy to delay the onset of this inherited disorder, based on the consumption of caffeine. Finally, it provides the first suggestion that A 2A R might be a novel therapeutic target to interfere with the inexorable evolution of this neurodegenerative disease. inclusions, whereas overt neuronal damage occurred later in the development of the disease.
Microgliosis would probably be found at later time-points, however, that was not evaluated. 
